Hemispherx Announces Alpha-N3 is Active Compared to Two H7N9 Virus Types

Hemispherx Biopharma (NYSE: HEB ) announced that at the 53rd annual meeting of Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Denver, Colorado during September 9-13, 2013, that William Mitchell, MD, Ph.D., Professor Pathology, Microbiology, and Immunology, Vanderbilt University, presented the results of a study of Hemispherx product, Alferon N Injection^®, the